Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Highlights: Participant screening closed for ATH434-201 Phase 2 studyIndependent Data Monitoring Committee recommended the ATH434-201 Phase 2 study continue as plannedReceived A$4.74M cash refund...

Related Keywords

San Francisco ,California ,United States ,Australia ,Melbourne ,Victoria ,Australian ,David Stamler ,Remy Bernarda ,Hannah Howlett ,European Patent Office ,Alterity Therapeutics Limited ,Alterity Therapeutics ,Movement Disorders ,International Congress ,Data Monitoring Committee ,Securities Exchange ,Australian Government Research ,Nasdaq ,Development Tax Incentive ,Australian Taxation Office ,Vanderbilt University Medical Center ,Company Phase ,Multiple System Atrophy ,European Patent ,Therapeutics Limited ,Quarterly Cash Flow Report ,Chief Executive Officer ,Australian Government ,Double Blind Phase ,Biomarker Phase ,Matter Patent Granted ,Media Contacts ,Securities Act ,Securities Exchange Act ,Annual Report ,Markets ,